SCHEMBL2869477

SCHEMBL2869477

CC(CNC(=O)CC1NC(=O)NC1=O)c1ccc(-c2cnc3ccccc3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 1/20 0.42
CASP1 P29466 1/20 0.42
KMT2A Q03164 1/20 0.42
F9 P00740 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
NTSR1 P30989 2/20 0.38
HSD17B10 Q99714 2/20 0.37
TDP2 O95551 1/20 0.37
ALOX15 P16050 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NR2F2 P24468 1/20 0.37
FASN P49327 1/20 0.37
MAP4K4 O95819 1/20 0.36
CSNK1G2 P78368 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870628 0.81 ALDH1A1 (0.42) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2875815 0.80 ALDH1A1 (0.48) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2874440 0.79 ALDH1A1 (0.45) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2872252 0.79 ALDH1A1 (0.47) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2874372 0.79 NR2F2 (0.39) F9AKR1C3AKR1C2NTSR1TDP2
SCHEMBL6188415 0.77 ALDH1A1 (0.52) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2873664 0.77 ALDH1A1 (0.46) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2870693 0.77 ALDH1A1 (0.44) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2869499 0.77 MAPT (0.45) ALDH1A1GAAKDM4EMEN1CASP1
SCHEMBL2871365 0.77 GAA (0.43) ALDH1A1GAAKDM4EMEN1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 US claimed
EP-1542977-B1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2006-12-20 EP claimed
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US claimed
EP-1542977-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. AstraZeneca AB (SE) 2005-06-22 EP claimed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 WO claimed
US-7662845-B2 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB (SE) 2010-02-16 US disclosed
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 US disclosed
EP-1542977-B1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2006-12-20 EP disclosed
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB, A SWEDEN CORPORATION 2006-12-07 US disclosed
US-20050288273-A1 Antibacterial agents BOYER FREDERICK E JR 2005-12-29 US disclosed
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US disclosed
EP-1542977-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. AstraZeneca AB (SE) 2005-06-22 EP disclosed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 MMP12, MMP13, MMP9 ALDH1A1 540/4885GAA 440/4885KDM4E 495/4885
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 MMP12, PDE12, MMP13 ALDH1A1 441/4885GAA 491/4885KDM4E 553/4885
US-20050288273-A1 Antibacterial agents MRPL21, RPN2, FBL ALDH1A1 637/4885GAA 91/4885KDM4E 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.